Technology
Health
Pharmaceutical

Innoviva

$13.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Innoviva and other stocks, options, ETFs, and crypto commission-free!

About

Innoviva, Inc. Common Stock, also called Innoviva, is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Read More Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.

Employees
6
Headquarters
Brisbane, California
Founded
1996
Market Cap
1.39B
Price-Earnings Ratio
3.89
Dividend Yield
0.00
Average Volume
983.22K
High Today
$13.86
Low Today
$13.55
Open Price
$13.71
Volume
276.95K
52 Week High
$20.54
52 Week Low
$13.26

Collections

Technology
Health
Pharmaceutical
Medical
Finance
US
North America

News

Simply Wall StMar 7

Does Innoviva, Inc. (NASDAQ:INVA) Have A Volatile Share Price?

Anyone researching Innoviva, Inc. (NASDAQ:INVA) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the portfolio. The other type, which cannot be diversified away, is the volatility of the entire m...

83
MarketBeatFeb 27

Stock Price, News, & Analysis for Innoviva

Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was...

10
Guru FocusFeb 19

Innoviva Inc (INVA) Files 10-K for the Fiscal Year Ended on December 31, 2018

Innoviva Inc (NASDAQ:INVA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines.

0

Earnings

$0.27
$0.40
$0.52
$0.65
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 25, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.